Latest News
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown
On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.
HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity
ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.
A Journey of a Thousand Miles Begins with a Single Step Navigating the Path to a Leadership Position
In this personal reflection from the latest issue of HOPA News, Mary Walters, PharmD, BCOP, and Peter Stuessy, PharmD, BCOP, compare and contrast their journeys into leadership roles - and what advice they would give others on their own leadership paths.
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
